PARP1 and breast carcinoma: developed the first dual VEGFR/PARP inhibitor, which inhibits angiogenesis and invasion by negatively regulating the expression of VEGFR and PARP, thereby suppressing the growth and metastasis of BRCA wild-type breast cancer (118).